Optimization of composition of ormustine liposomal dosage form

L. L. Nikolaeva; A. V. Lantsova; E. V. Sanarova; A. P. Polozkova; O. L. Orlova; N. A. Oborotova

doi:10.1134/S1995078016030125

Optimization of composition of ormustine liposomal dosage form

Authors: Nikolaeva L.L.¹, Lantsova A.V.¹, Sanarova E.V.¹, Polozkova A.P.¹, Orlova O.L.¹, Oborotova N.A.¹
Affiliations:
1. Blokhin Russian Cancer Research Center
Issue: Vol 11, No 5-6 (2016)
Pages: 371-376
Section: Article
URL: https://journal-vniispk.ru/2635-1676/article/view/219412
DOI: https://doi.org/10.1134/S1995078016030125
ID: 219412

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

The improvement of the composition and technology for the preparation of the liposomal dosage form of ormustine is under consideration. Liposomes are prepared from egg lecithin, cholesterol, and PEG-2000-DSPE by the film hydration method, with 0.1% citric acid being added to the composition to stabilize the liposome dispersion. The efficiency of loading with ormustine is (60 ± 5)% and the average vesicle size is (190 ± 20) nm.